Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Assertio Therapeutics Inc (ASRT)

Assertio Therapeutics Inc (ASRT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,044
  • Shares Outstanding, K 80,681
  • Annual Sales, $ 311,770 K
  • Annual Income, $ 36,910 K
  • 60-Month Beta 1.99
  • Price/Sales 0.37
  • Price/Cash Flow 0.50
  • Price/Book 0.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +42.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.01 +15.84%
on 01/06/20
1.69 -30.77%
on 12/27/19
+0.07 (+6.85%)
since 12/23/19
3-Month
0.68 +71.33%
on 12/09/19
1.69 -30.77%
on 12/27/19
+0.28 (+30.86%)
since 10/23/19
52-Week
0.68 +71.33%
on 12/09/19
5.76 -79.69%
on 04/05/19
-2.76 (-70.23%)
since 01/23/19

Most Recent Stories

More News
Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?

Is (ASRT) Outperforming Other Medical Stocks This Year?

ASRT : 1.17 (-5.65%)
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Assertio (ASRT) closed at $1.14, marking a -1.72% move from the previous day.

ASRT : 1.17 (-5.65%)
ASRT or PCRX: Which Is the Better Value Stock Right Now?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT : 1.17 (-5.65%)
PCRX : 43.94 (-1.24%)
Assertio Therapeutics Announces Closing of Gralise(R) Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance

Assertio Therapeutics, Inc. ("Assertio" or "The Company") (NASDAQ: ASRT), today announced the closing of its previously disclosed agreement ("Agreement") with Alvogen, a global privately held pharmaceutical...

ASRT : 1.17 (-5.65%)
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know

Assertio (ASRT) closed the most recent trading day at $1.07, moving -0.93% from the previous trading session.

ASRT : 1.17 (-5.65%)
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up

Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.

EGRX : 57.98 (+0.12%)
CORT : 13.13 (+0.23%)
TYME : 1.65 (-7.82%)
ASRT : 1.17 (-5.65%)
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA

The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).

CORT : 13.13 (+0.23%)
ACRX : 1.71 (-3.39%)
XON : 5.90 (+0.25%)
ASRT : 1.17 (-5.65%)
Catalyst Gives Preliminary Firdapse Estimates & Other Updates

Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.

CPRX : 4.20 (+1.94%)
CORT : 13.13 (+0.23%)
ACRX : 1.71 (-3.39%)
ASRT : 1.17 (-5.65%)
ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT : 1.17 (-5.65%)
PCRX : 43.94 (-1.24%)
Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock?

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ASRT : 1.17 (-5.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ASRT with:

Business Summary

Assertio Therapeutics, Inc. is a pharmaceutical company. It develops and markets a product for the treatment in neurology, orphan and diseases of the central nervous system. Assertio Therapeutics, Inc., formerly known as Depomed Inc., is headquartered in Lake Forest, Illinois.

See More

Key Turning Points

2nd Resistance Point 1.29
1st Resistance Point 1.23
Last Price 1.17
1st Support Level 1.14
2nd Support Level 1.11

See More

52-Week High 5.76
Fibonacci 61.8% 3.82
Fibonacci 50% 3.22
Fibonacci 38.2% 2.62
Last Price 1.17
52-Week Low 0.68

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar